This news release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the interpretation and potential relevance of CONVERGE and other real-world evidence; the potential benefits, characteristics and market adoption of ZUNVEYL; and the Company’s evidence-generation, clinical-development and commercialization plans. Forward-looking statements are based on management’s current expectations, assumptions and beliefs and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. These risks include risks related to the interpretation, completeness and generalizability of retrospective real-world data; confounding, selection bias, data quality and differences among treatment cohorts; commercial adoption, reimbursement, manufacturing and supply; regulatory oversight and pharmacovigilance; clinical-development timing and outcomes; intellectual property; liquidity and financing; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement.